BiotechTube

Lenvatinib + Lenvatinib + Lenvatinib + Lenvatinib + Lenvatinib + Ifosfamide + Etoposide + Ifosfamide + Etoposide

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tumors

Conditions

Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)

Trial Timeline

Dec 29, 2014 → Jul 20, 2022

NCT ID
NCT02432274

About Lenvatinib + Lenvatinib + Lenvatinib + Lenvatinib + Lenvatinib + Ifosfamide + Etoposide + Ifosfamide + Etoposide

Lenvatinib + Lenvatinib + Lenvatinib + Lenvatinib + Lenvatinib + Ifosfamide + Etoposide + Ifosfamide + Etoposide is a phase 1/2 stage product being developed by Eisai for Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02432274. Target conditions include Tumors, Solid Malignant Tumors, Osteosarcoma.

What happened to similar drugs?

8 of 20 similar drugs in Tumors were approved

Approved (8) Terminated (4) Active (8)
✅Everolimus (RAD001)NovartisApproved
✅everolimusNovartisApproved
✅Imatinib MesylateNovartisApproved
✅NilotinibNovartisApproved
✅Sacituzumab Govitecan-hiyGilead SciencesApproved
✅Binimetinib only treatment + Encorafenib only Treatment + Encorafenib & Binimetinib Treatment + Treatment of Encorafenib & Binimetinib & Ribociclib + Treatment of Encorafenib & Binimetinib & CetuximabPfizerApproved
✅Sunitinib Malate (SU011248)PfizerApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02432274Phase 1/2Completed

Competing Products

20 competing products in Tumors

See all competitors
ProductCompanyStageHype Score
mRNA-4359ModernaPhase 2
0
mRNA-4106ModernaPhase 1
0
mRNA-4157 + Pembrolizumab + SoC TreatmentMerckPhase 1
33
E7050EisaiPhase 1
29
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
CixutumumabEli LillyPhase 1
29
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
27
ZN-c3 + Bevacizumab + PembrolizumabZentalis PharmaceuticalsPhase 1
11
IMC-18F1Eli LillyPhase 1
29
OKI-179OnKure TherapeuticsPhase 1
19
ACR-2316Acrivon TherapeuticsPhase 1
26
LY2875358 + Erlotinib + GefitinibEli LillyPhase 1
29
Tomivosertib (eFT-508)eFFECTOR TherapeuticsPhase 2
25
SPYK04Chugai PharmaceuticalPhase 1
33
AUBE00 + CetuximabChugai PharmaceuticalPhase 1
36
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
21
ERY974Chugai PharmaceuticalPhase 1
29
DS3610aDaiichi SankyoPhase 1
36
Tivantinib (ARQ 197) Capsule + Tivantinib (ARQ 197) Tablet + Tivantinib (ARQ 197) Capsule D, oralDaiichi SankyoPhase 1
29